Species |
Human |
Protein Construction |
Expressed with additional C-terminal sequence (GYGRKKRRQRRR).
p16-TAT (Glu2-Asp156) Accession # P42771 |
|
Purity |
> 95% as analyzed by SDS-PAGE > 95% as analyzed by HPLC |
Endotoxin Level |
< 1 EU/μg of protein by LAL method |
Expression System |
E. coli |
Theoretical Molecular Weight |
18 kDa |
Formulation |
Lyophilized from a 0.2 μm filtered solution in 2 × PBS, pH 7.0. |
Reconstitution |
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/ml. |
Storage & Stability |
Upon receiving, this product remains stable for up to 6 months at -70°C or -20°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. Avoid repeated freeze-thaw cycles. |
Target Background |
Cyclin-dependent kinase inhibitors (CDKIs) are proteins that bind to and inhibit the activity of CDKs. Two major classes of CDK inhibitors have been identified. The p16 family (p15, p16, p18 and p19) binds to and inhibits the activities of CDK4 and CDK6. The p21 family (p21, p27, p28 and p57) can bind to broad range of CDK-cyclin complexes and inhibit their activities. CDKIs are capable of suppressing growth, and several lines of evidence strongly suggest that at least some CDKIs may be tumor suppressor proteins. |
Synonyms |
Cyclin-dependent kinase inhibitor 2A; Cyclin-dependent kinase 4 inhibitor A; CDK4I; p16INK4A; p16-INK4; Multiple tumor suppressor 1; MTS-1 |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.